The Prevention Options for Women Evaluation Research (POWER) Cohort

CompletedOBSERVATIONAL
Enrollment

2,255

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

December 4, 2020

Study Completion Date

July 23, 2021

Conditions
HIV/AIDS
Interventions
DRUG

Truvada

A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.

Trial Locations (3)

Unknown

Kenya Medical Research Institute, Kisumu

Desmond Tutu HIV Foundation, Cape Town

Wits Reproductive Health and HIV Institute, Johannesburg

Sponsors
All Listed Sponsors
collaborator

Desmond Tutu HIV Foundation

OTHER

collaborator

Wits Reproductive Health and HIV Institute

OTHER

collaborator

Kenya Medical Research Institute

OTHER

collaborator

United States Agency for International Development (USAID)

FED

collaborator

RTI International

OTHER

collaborator

Harvard Medical School (HMS and HSDM)

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Washington

OTHER